Cabamiquine

DB21477InvestigationalSmall molecule

Cabamiquine is a small molecule drug. Cabamiquine is under investigation in clinical trial NCT05974267 (Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents... Cabamiquine has a monoisotopic molecular weight of 462.24 Da.

Mechanism: Pharmacologically active on Elongation factor 2
Curator reviewed
Formula / weight: C₂₇H₃₁FN₄O₂ · 462.569 g/mol (avg)
Code names: DDD-107498 · DDD498 · M-5717 · MMV-121

Resolves to

Compound

UNIIE3OC1CU1F4CAS1469439-69-7ChEMBLCHEMBL4091762ChEBI756594PubChem71748268

Structure

InChIKeyBENUHBSJOJMZEE-UHFFFAOYSA-NSMILESFC1=CC2=C(C=C(N=C2C=C1)C1=CC=C(CN2CCOCC2)C=C1)C(=O)NCCN1CCCC1

Targets

Q8IKW5Elongation factor 2

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cabamiquine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account